EU regulator rejects Alzheimer’s drug lecanemab
It said the benefits of the treatment did not outweigh the risk of serious side effects….Read more.
EU regulator rejects Alzheimer’s drug lecanemab
It said the benefits of the treatment did not outweigh the risk of serious side effects….Read more.